| ReNerve Limited (RNV) ORDINARY FULLY PAID |
Health Care |
$12 |
Application for quotation of securities - RNV
|
18 Feb 2026 8:17AM |
$0.115 |
$0.083 |
fallen by
27.83%
|
|
| Pioneer Credit Limited (PNC) ORDINARY FULLY PAID |
Financials |
$90 |
Notification regarding unquoted securities - PNC
|
18 Feb 2026 8:17AM |
$0.745 |
$0.560 |
fallen by
24.83%
|
|
| SHAPE Australia Corporation Limited (SHA) ORDINARY FULLY PAID |
Industrials |
$630 |
Dividend/Distribution - SHA
|
18 Feb 2026 8:17AM |
$6.520 |
$7.540 |
risen by
15.64%
|
|
| Dyno Nobel Limited (DNL) ORDINARY FULLY PAID |
Materials |
$6,390 |
Update - Notification of buy-back - DNL
|
18 Feb 2026 8:17AM |
$3.310 |
$3.640 |
risen by
9.97%
|
|
| SHAPE Australia Corporation Limited (SHA) ORDINARY FULLY PAID |
Industrials |
$630 |
Appendix 4D and Half Year Report
|
18 Feb 2026 8:17AM |
$6.520 |
$7.540 |
risen by
15.64%
|
|
SHA - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 15.5% to $553.3 million.
- Profit after tax rose by 48.5% to $13.995 million.
- EBITDA increased by 44.5% to $21.372 million.
- Acquisition of Arden Group added $27.2 million in goodwill.
- Interim dividend declared at 14 cents per share.
- Strong liquidity with $106.1 million in cash.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tartana Minerals Limited (TAT) ORDINARY FULLY PAID |
Materials |
$7 |
Application for quotation of securities - TAT
|
18 Feb 2026 8:17AM |
$0.038 |
$0.021 |
fallen by
44.74%
|
|
| Aurizon Holdings Limited (AZJ) ORDINARY FULLY PAID |
Industrials |
$7,137 |
Update - Notification of buy-back - AZJ
|
18 Feb 2026 8:17AM |
$3.940 |
$4.240 |
risen by
7.61%
|
|
| 1414 Degrees Limited (14D) ORDINARY FULLY PAID |
Industrials |
$41 |
Change in substantial holding
|
18 Feb 2026 8:16AM |
$0.023 |
$0.081 |
risen by
252.17%
|
|
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$47,915 |
Update - Notification of buy-back - CSL
|
18 Feb 2026 8:16AM |
$151.560 |
$100.050 |
fallen by
33.99%
|
|
| Euro Manganese Inc (EMN) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$5 |
Management Discussion & Analysis for Quarter ended 12/31/25
|
18 Feb 2026 8:16AM |
$0.195 |
$0.125 |
fallen by
35.90%
|
|
EMN - Price-sensitive ASX Announcement
Full Release
Key Points
- Euro Manganese focuses on the Chvaletice Project with 100% ownership interest.
- The company reported a comprehensive loss of $3.648 million for the quarter ending December 31, 2025.
- Amendments to the Orion Funding Package extended certain milestone dates.
- Ongoing financial uncertainties affect project advancement due to funding challenges.
- EMN aims to produce high-purity manganese products for electric vehicle markets.
- Chvaletice Manganese Project involves reprocessing a manganese deposit in the Czech Republic.
- The company faces liquidity challenges with a working capital deficit of $25.666 million.
- Successful demonstration of high-purity manganese production was achieved.
- Negotiations for land acquisitions and project financing are ongoing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cochlear Limited (COH) ORDINARY FULLY PAID |
Health Care |
$6,337 |
Appendix 3Y - Richard Freudenstein
|
18 Feb 2026 8:16AM |
$199.810 |
$96.890 |
fallen by
51.51%
|
|
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$4,799 |
Telix Submits EU MAA for TLX101-Px Brain Cancer Imaging
|
18 Feb 2026 8:16AM |
$8.840 |
$14.140 |
risen by
59.95%
|
|
TLX - Price-sensitive ASX Announcement
Full Release
Key Points
- Telix submits European MAA for TLX101-Px.
- TLX101-Px aims to improve glioma imaging in Europe.
- Submission involves collaboration with European regulatory agencies.
- Regulatory alignment with U.S. FDA package expedites EU filing.
- TLX101-Px to potentially aid Telix's glioblastoma therapy assessments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Euro Manganese Inc (EMN) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$5 |
Interim Financial Statements for Quarter ended 12/31/25
|
18 Feb 2026 8:16AM |
$0.195 |
$0.125 |
fallen by
35.90%
|
|
EMN - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss for the quarter was $3.633 million.
- Revenues increased to $1.147 million.
- Significant expenses for the Chvaletice Project evaluation at $1.497 million.
- Total assets were $33.544 million, with liabilities at $34.220 million.
- Development focus on the Chvaletice Manganese Project and potential Canadian opportunities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Healius Limited (HLS) ORDINARY FULLY PAID |
Health Care |
$258 |
Healius announces 1H 2026 results
|
18 Feb 2026 8:16AM |
$0.815 |
$0.355 |
fallen by
56.44%
|
|
HLS - Price-sensitive ASX Announcement
Full Release
Key Points
- Group revenue up 3.8% to $688.1 million.
- Underlying EBITDA up 13.1% to $122.2 million.
- Underlying EBIT $7.9 million from a loss in 1H25.
- Pathology revenue increased by 3.5%.
- Agilex revenue grew by 16.0%.
- Cost management limited increase to 1.9%.
- Implementation of AI and digital solutions.
- Contract with Australian Department of Defence worth $60 million.
- High single-digit EBIT margins expected by June 2027.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Endeavour Group Limited (EDV) ORDINARY FULLY PAID |
Consumer Staple |
$5,549 |
Endeavour Group Board Update
|
18 Feb 2026 8:16AM |
$3.840 |
$3.090 |
fallen by
19.53%
|
|
| Healius Limited (HLS) ORDINARY FULLY PAID |
Health Care |
$258 |
Half Year 2026 Results Presentation
|
18 Feb 2026 8:16AM |
$0.815 |
$0.355 |
fallen by
56.44%
|
|
HLS - Price-sensitive ASX Announcement
Full Release
Key Points
- Healius Limited reported a group revenue growth of $25.5 million, an increase of 3.8%, to $688.1 million for the first half of 2026.
- Pathology revenue rose by $22.5 million, or 3.5%, reaching $666.3 million.
- The group's underlying EBITDA increased by $14.2 million, marking a 13.1% rise to $122.2 million.
- Pathology's EBITDA went up by $12.3 million (11.7%) to $117.4 million, while Agilex Biolabs' EBITDA increased by $1.9 million (65.5%) to $4.8 million.
- A significant technology investment was made, including the launch of AI co-workers and the Medway Collectors and Results Portals.
- The company achieved a net cash position of $11.6 million by the end of December 2025.
- Healius is focused on cost reduction strategies, resulting in annualized support cost savings and a digital transformation program.
- Labour optimization and cost management have been key drivers for the operational efficiency gains reported.
- The strategic pivot towards large molecule work by Agilex Biolabs has contributed positively to margin expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Healius Limited (HLS) ORDINARY FULLY PAID |
Health Care |
$258 |
Half Yearly Report and Accounts
|
18 Feb 2026 8:16AM |
$0.815 |
$0.355 |
fallen by
56.44%
|
|
HLS - Price-sensitive ASX Announcement
Full Release
Key Points
- Net comprehensive loss for the period was $30.8 million.
- Reported net loss after tax was $30.4 million.
- Revenue increased by 3.8% to $688.1 million.
- Underlying EBITDA increased by 13.1% to $122.2 million.
- Financial pressures in the pathology sector due to non-indexation of Medicare Benefits Schedule.
- Rising employment costs following Fair Work Commission decision.
- Continued demand for pathology services driven by aging population and genomic diagnostics.
- Total assets amounted to $1,773.5 million.
- Total liabilities were $1,216.4 million.
- Net assets were reported at $557.1 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 5E Advanced Materials Inc. (5EA) CHESS DEPOSITARY INTERESTS 10:1 |
Materials |
$4 |
5EA - Form 10-Q - Quarterly Results 31 December 2025
|
18 Feb 2026 8:15AM |
$0.325 |
$0.235 |
fallen by
27.69%
|
|
5EA - Price-sensitive ASX Announcement
Full Release
Key Points
- 5E Advanced Materials is focused on borates and advanced boron materials.
- Quarterly report for period ending December 31, 2025.
- Executed a reverse stock split in February 2025.
- Reported ongoing financial challenges and reliance on financing.
- Substantial doubt about the company's ability to continue without additional funding.
- Continues development of the 5E Boron Americas Complex.
- Emphasizes sustainable and secure supply of critical materials.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| St Barbara Limited (SBM) ORDINARY FULLY PAID |
Materials |
$665 |
Change in substantial holding
|
18 Feb 2026 8:15AM |
$0.735 |
$0.550 |
fallen by
25.17%
|
|
| Euro Manganese Inc (EMN) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$5 |
Euro Manganese Announces Appointment of Director
|
18 Feb 2026 8:15AM |
$0.195 |
$0.125 |
fallen by
35.90%
|
|
| Percheron Therapeutics Limited (PER) ORDINARY FULLY PAID |
Health Care |
$6 |
Percheron Therapeutics Limited - Corporate Presentation
|
18 Feb 2026 8:15AM |
$0.007 |
$0.004 |
fallen by
42.86%
|
|
| Alcoa Corporation (AAI) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$3,393 |
Change in substantial holding
|
18 Feb 2026 8:15AM |
$83.010 |
$89.900 |
risen by
8.30%
|
|
| Australian Finance Group Ltd (AFG) ORDINARY FULLY PAID |
Financials |
$436 |
AFG FY26 Half Year Results Investor Presentation
|
18 Feb 2026 8:15AM |
$2.040 |
$1.605 |
fallen by
21.32%
|
|
AFG - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit for H1 FY26 up by 43% to $24 million.
- Subscription income increased by 11%, now 20% of distribution gross profit.
- Eight consecutive years of growth in broker services income.
- Operating expenses increased by $0.7 million, primarily due to technology enhancements and broker engagement.
- AFG Securities reported a 99% increase in lodgement growth.
- Transition to higher margin AFG Securities products as white label volumes reduce.
- Net cash from operating activities rose by 50% to $20 million.
- Underlying return on equity increased to 21%.
- Declared interim dividend of 4.7 cents per share for FY26.
- Focus on leveraging network scale and investing in high-return segments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Finance Group Ltd (AFG) ORDINARY FULLY PAID |
Financials |
$436 |
AFG FY26 Half Year Results Market Release
|
18 Feb 2026 8:14AM |
$2.040 |
$1.605 |
fallen by
21.32%
|
|
AFG - Price-sensitive ASX Announcement
Full Release
Key Points
- Record half-year result for AFG with NPAT up 46% to $22.4 million.
- Underlying gross profit increased 16% to $79 million.
- EBITDA surged 43% to $35.6 million.
- AFG brokers now write 1 in 9 residential home loans nationally.
- AFG Securities achieved a record loan book of $6.3 billion.
- BrokerEngine Plus adoption increased by 23%, with subscription income up 11%.
- Reduced cost-to-income ratio to 56%.
- Favorable funding terms reduced sensitivity to cash rate changes.
- Strategic focus on broker network expansion and technology enhancements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Finance Group Ltd (AFG) ORDINARY FULLY PAID |
Financials |
$436 |
Dividend/Distribution - AFG
|
18 Feb 2026 8:14AM |
$2.040 |
$1.605 |
fallen by
21.32%
|
|
Call 1300 880 160
Start a chat
Schedule a call
